In The Spotlight


cannabisleaf-nov19.jpg Of late, cannabis-related news and stocks have been garnering a lot of investor attention. Let's take a look at some of them.

liquida-nov15.jpg Shares of Liquidia Technologies Inc. (LQDA), which recently debuted on Nasdaq, are down more than 40% from their latest high.

maciepicel-nov07.jpg Shares of Vericel Corporation (VCEL) have gained an impressive 200% year-to-date, way ahead of the mere 0.9% returned by iShares Nasdaq Biotechnology ETF (IBB) for the same period.

immypharma-oct25.jpg Shares of Imprimis Pharmaceuticals Inc. (IMMY) have returned more than 110% year-to-date while the iShares Nasdaq Biotechnology ETF (IBB) has fallen 4% during the same period.

akorn-stock-rebound-101818.jpg Shares of Akorn Inc. (AKRX) have lost nearly 78% of their value year-to-date while the iShares NASDAQ Biotechnology Index (IBB) is up 7% for the same period.

investors-chart-101018.jpg Shares of Epizyme Inc. (EPZM) have lost 50% of their value over the last 7 months compared to the 1.2 % gain of the iShares Nasdaq Biotechnology ETF (IBB) index during the same period.

sea-spine-100318.jpg Shares of SeaSpine Holdings Corp. (SPNE) have returned more than 60% year-to-date, clearly outpacing the 12% gain of the iShares Nasdaq Biotechnology index.

oasmia-sept27.jpg The American Depositary Shares of Oasmia Pharmaceutical AB (OASM), which touched a new 52-week high of $5.70 Wednesday (Sep.26), have gained more than 400% this year.

antarecpharma-sept20.jpg Shares of Antares Pharma Inc. (ATRS) have lost nearly 7% of their value so far this month, as the company's regulatory catalyst draws closer. Antares Pharma is a revenue-generating, specialty pharmaceutical company, focusing on self-injection pharmaceutical products and technologies, and topical gel-based products.

septembercl-sep12.jpg Shares of Arena Pharmaceuticals Inc. (ARNA) have returned 18% year-to-date, nearly double the gain of the Nasdaq Biotechnology index.

prodex-sep6.jpg Shares of Pro-Dex Inc. (PDEX), which touched a new 52-week high of $11 in intraday trading yesterday, have yielded a decent return of 44% year-to-date.

axsome-aug29.jpg Shares of Axsome Therapeutics Inc. (AXSM) have returned 15% so far this month while the iShares Nasdaq Biotechnology ETF (IBB) has gained just 3% for the same period.

mesoblast-aug23.jpg The American depository shares of Australian company Mesoblast Limited (MESO) have returned a mere 2% year-to-date, lagging behind the iShares Nasdaq Biotechnology ETF (IBB) Index's gain of nearly 10%.

Follow RTT